December 5, 2022
Mochida Pharmaceutical will be responsible for the domestic marketing of Eli Lilly Japan’s ulcerative colitis drug candidate mirikizumab once it is approved, the two companies said on December 2. Under the alliance deal, Lilly will be supplying mirikizumab in Japan...read more